All News

Adding local radiotherapy to hormonal treatment more than halves long-term prostate cancer-specific mortality and substantially decreases overall mortality in men with non-metastatic locally advanced or high-risk prostate cancer, according to an updated analysis of clinical trial data from the Scandinavian Prostate Cancer Group’s Study VII.

Three-dimensional mapping biopsy (3DMB) of the prostate provides a more accurate disease assessment and in doing so may allow more confident decision making when patients and their physicians are trying to resolve issues surrounding observation or more aggressive therapies, a study from the University of Colorado School of Medicine, Denver, suggests.

A study from Memorial Sloan-Kettering Cancer Center, New York sheds light on the “obesity paradox” seen with renal cell carcinoma while at the same time demonstrating the emerging value of genomics in understanding cancer and other diseases.

Higher PSA density at diagnosis is associated with biopsy progression of low-risk prostate cancer in patients enrolled in active surveillance.

Researchers at the University of North Carolina School of Medicine, Chapel Hill, have identified a discrete set of genes that segregate high-grade bladder cancer into two distinct subtypes-basal-like and luminal-each of which appears to have its own molecular characteristics and outcome. The authors also found that the two subtypes share many of the characteristics seen in basal and luminal breast cancer subtypes, a discovery with clinical implications.

Dose-escalated intensity-modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4-Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a recently published study.

Among men undergoing radiation therapy for prostate cancer, daily use of the phosphodiesterase type-5 inhibitor tadalafil (Cialis), compared with placebo, did not prevent loss of erectile function, a recently published study found.

This guide features products and services from manufacturers that are exhibiting at the AUA annual meeting in Orlando. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.

The 2014 Urology Joint Advocacy Conference (JAC), co-sponsored by the American Association of Clinical Urologists and the American Urological Association, turned out to be an opportune time for urologists visiting Capitol Hill.

The AUA returns to Orlando-one of the nation’s most family-friendly, fun cities-for its 2014 annual meeting, May 16-21. Although this central Florida town is most frequently associated with a certain beloved mouse-and Disney’s many parks are well worth a visit, regardless of your age-there are plenty of other activities to make all ages smile.

In his latest blog post, Henry Rosevear, MD, summarizes the Affordable Care Act and explains how it has already affected his practice.

Three professional medical societies and an international group of 130 scientists and physicians have petitioned JAMA to retract a recent article that reported an association between the use of testosterone therapy and increased risk of death, heart attack, or ischemic stroke.

Cholesterol-lowering statin drugs are associated with a significant improvement in erectile function, cardiologists reported in a new meta-analysis.

Laser photoselective vaporization prostatectomy is permitting surgical intervention for BPH in a widening array of patients, many of whom harbor comorbidities that would ordinarily exclude them from invasive procedures, according to a new multinational report.

New AUA Director of Government Relations and Advocacy Brad Stine intends to advocate for the AUA’s SGR policy: to gain affirmative repeal of the formula that has proven so troublesome over the years for urologists, whose patient population includes a large percentage of Medicare enrollees.

The take-home message is that for sorafenib and sunitinib, sequencing does not appear to be drug dependent and either can be used as first- or second-line therapy.

A comprehensive molecular characterization of muscle-invasive urothelial bladder carcinoma suggests multiple opportunities for therapeutic intervention.

Primary androgen deprivation therapy in men with localized prostate cancer appears to offer no survival benefit.

A collaborative effort involving Duke University experts in urology, engineering, pathology, and mathematics has resulted in improved efficiency for shock wave lithotripsy, the researchers report.

There are two accepted versions of the E&M documentation guidelines that have been released by the Centers for Medicare & Medicaid Services: one from 1995 and another from 1997. The main difference between the guidelines lies in the detail that surrounds the appropriate level of documentation for physical examination.

The investigational 17,20 lyase inhibitor orteronel failed to significantly extend overall survival in an international phase III study of patients with metastatic castration-resistant prostate cancer.

Although the activity of enzalutamide (XTANDI) is blunted in patients with metastatic castration-resistant prostate cancer who have been treated previously with abiraterone acetate (ZYTIGA), a meaningful number of these patients still experience a decline in PSA level with enzalutamide, according to a recent study.

The sequential use of two targeted treatments for metastatic renal cell carcinoma appears to yield similar total progression-free survival regardless of the order in which they are given, phase III study results indicate.

Urologists' opinions on EHR systems vary, as some feel that they're helpful in large systems where paper records are not always on hand, while others lament the lost time spent communicating face-to-face with patients.

Testosterone replacement therapy (TRT) in hypogonadal men does not appear to increase the risk for prostate cancer, according to an evaluation of 224 men with an indication for prostate biopsy, providing further evidence that TRT need not be avoided in this patient group.

A study from the UCLA Ronald Reagan Medical Center appears to once again prove that time is money. The study’s findings indicate that up to $15 million could be saved annually by referring patients who are candidates for robot-assisted radical prostatectomy to surgeons and surgical centers with optimal operating times.

Astellas Pharma Inc. and Medivation Inc. have submitted a supplemental new drug application to the FDA seeking approval of enzalutamide (XTANDI) capsules for the treatment of men with metastatic castration-resistant prostate cancer who have not received chemotherapy.

J. Stuart Wolf, MD, will serve as the first chair of the AUA’s newly created Science & Quality (S&Q) Council, the association announced.

The Centers for Medicare & Medicaid Services has issued two new codes that describe the UroLift implant procedure for the treatment of enlarged prostate in the April 2014 Update of the Hospital Outpatient Prospective Payment System (OPPS).

Patients are demanding transparency and access to their health information, and recent initiatives from the government and private insurers are addressing these demands.